Company Overview and News
KUALA LUMPUR (Aug 7): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Dufu Technology Corp Bhd, Frontken Corp Bhd, Tien Wah Press Holdings Bhd, Hartalega Holdings Bhd, Uzma Bhd, Inta Bina Group Bhd, Metronic Global Bhd, Advancecon Holdings Bhd, Three-A Resources Bhd, KKB Engineering Bhd, Versatile Creative Bhd and MISC Bhd.
0012 4995 5347 TNABY TNABF 5168 7374 9466 0043 7233 HRGHY
KUALA LUMPUR (Aug 7): Metronic Global Bhd (MGB) has bagged a RM6.04 million contract to supply, deliver, install, test and commission audio visual system for Lot 91 Convention Centre Podium at Kuala Lumpur City Centre.
BSMAF 4596 0043 1818
KUALA LUMPUR (June 11): Based on corporate announcements and news flow today, companies in focus on Tuesday (June 12) may include: Sapura Energy Bhd, RHB Bank Bhd, Bina Darulaman Bhd, Daya Materials Bhd, Metronic Global Bhd, Meda Inc Bhd and Gas Malaysia Bhd.
4634 6173 5209 0091 BSMAF 0043 7078 1818
KUALA LUMPUR (June 11): Metronic Global Bhd‘s wholly-owned subsidiary Metronic Engineering Sdn Bhd has been awarded 4.73 million Saudi Arabian riyals (RM5 million) in an adjudication proceeding against Ahmad Zaki Resources Bhd.
BSMAF 0043 7078 1818
2018-03-30 thestar.com.my - 1
PETALING JAYA: Metronic Global Bhd , a specialist in intelligent building management and integrated security management systems, has been awarded a RM50mil contract by Mass Rapid Transit Corp Sdn Bhd (MRT Corp) to install an underground building management system for the Sungai Buloh – Serdang Putrajaya MRT line.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...